Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05640102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

StatusRecruiting
PhaseNot specified
SponsorBeiGene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 8 sitesv25
  2. Re-verified, no change to tracked fieldsv24
  3. Study sites: 9 to 8v23
  4. Study sites: 11 to 9v22
  5. Site details revised at 1 of 11 sitesv21
Show 19 earlier versionsHide 19 earlier versions
  1. Study sites: 15 to 11v20
  2. Study sites: 16 to 15v19
  3. Site details revised at 1 of 16 sitesv18
  4. Site details revised at 1 of 16 sitesv17
  5. Study sites: 17 to 16v16
  6. Site details revised at 15 of 17 sitesv15
  7. Study sites: 16 to 17v14
  8. Study sites: 6 to 16v13
  9. Study sites: 16 to 6v12
  10. Study sites: 15 to 16v11
  11. Study sites: 11 to 15v10
  12. Study sites: 10 to 11v9
  13. Study sites: 9 to 10v8
  14. Study sites: 8 to 9v7
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 8 · Start date changed from estimate of Sep 29, 2023 to Mar 3, 2023v6 Show 2 more changesShow less
    • Study sites: 0 to 8
    • Start date changed from estimate of Sep 29, 2023 to Mar 3, 2023
  16. Start date: Jul 31, 2023 to Sep 29, 2023v5
  17. Start date: Jun 30, 2023 to Jul 31, 2023v4
  18. Start date: Apr 28, 2023 to Jun 30, 2023v3
  19. Start date: Dec 2022 to Apr 28, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BeiGene
37 trials monitored
See 1 trial at risk
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Trial Details
NCT Number NCT05640102
Lead Sponsor BeiGene
Conditions Waldenstrom Macroglobulinemia
Enrollment 111 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov